Fig. 1

This figure shows the time course of the patient presented. She was started on pembrolizumab 200 mg every three weeks from September 24, 2019, and presented with neuroinflammatory adverse effect 2 weeks later. The patient received pulse therapy with 1000 mg methylprednisolone intravenous daily after admission. Because of improvement in adverse effect, she was discharged with oral prednisolone 15 mg twice daily.